16 September 2026 editorial review · Trial
T1DAL: Alefacept in new-onset type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Explained registry termination was manufacturer’s business discontinuation of Amevive, not proof of futility; preserved nonsignificantprimary 12-month outcome and separate secondary follow-up.
Registry: NCT00965458; TERMINATED; updated 2017-07-06; enrollment 49 (ACTUAL); results posted.
Endpoint comparison: 2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT) (Baseline (pre-treatment initiation), Week 52).
Sources for this record: Targeting of memory T cells with alefacept in new-onset type 1 diabetes (peer-reviewed); Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients (peer-reviewed); Inducing Remission in Type 1 Diabetes With Alefacept (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.